<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739046</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-IMGPB-2021-02</org_study_id>
    <nct_id>NCT04739046</nct_id>
  </id_info>
  <brief_title>An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy</brief_title>
  <official_title>A Single Arm, Open, Exploratory Clinical Trial to Evaluate Efficacy and Safety for Combination Treatment of Replication Competent Adenovirus Double Suicide Gene Therapy(Theragene®,Ad5-yCD/mutTKSR39rep-ADP) and Radiation Therapy in Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NewGenPharm Incoporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Replication-competent Adenovirus-mediated Double Suicide Gene Therapy&#xD;
      (Theragene®,Ad5-yCD/mutTKSR39rep-ADP) showed safety and anti-cancer effect in patients with&#xD;
      pancreatic cancer in phase I study.&#xD;
&#xD;
      From the experience of phase I study, the safety and efficacy of combination with standard&#xD;
      chemotherapy and radiation therapy with Theragene treatment will be assessed in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase IIa study of Replication-competent Adenovirus-mediated Double Suicide Gene Therapy&#xD;
      (Theragene®,Ad5-yCD/mutTKSR39rep-ADP) with radiation therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>the proportion of patients with advanced or metastatic cancer who have achieved complete response or partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>the proportion of patients with advanced or metastatic cancer who have achieved complete response, partial response or stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor marker test</measure>
    <time_frame>24 weeks</time_frame>
    <description>change of tumor marker in the process of assigned treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>median time from beginning of treatment to death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Theragene arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theragene arm</intervention_name>
    <description>Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy</description>
    <arm_group_label>Theragene arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with borderline resectable or locally advanced pancreatic cancer&#xD;
&#xD;
          -  Patients with histologically confirmed pancreatic adenocarcinoma&#xD;
&#xD;
          -  Patients with no evidence of peritoneal or hematogenous metastasis&#xD;
&#xD;
          -  Patients with ECOG performance status 0-1&#xD;
&#xD;
          -  Patients with renal function (Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥&#xD;
             50 mL/min/m²)&#xD;
&#xD;
          -  Patients with bone marrow function (WBC &gt; 4,000/uL or absolute neutrophil count ≥&#xD;
             1500/uL, PLT ≥ 100,000/uL, and Hemoglobin &gt; 10 g/dL)&#xD;
&#xD;
          -  Patients with liver function (Bilirubin &lt; 2.0 mg/dL and SGOT and SGPT &lt; 3 times upper&#xD;
             limit of normal (ULN))&#xD;
&#xD;
          -  Patients with agreement with informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of other cancer&#xD;
&#xD;
          -  Patients with recurred pancreatic cancer&#xD;
&#xD;
          -  Patients with a history of radiation on more than 25% of bone marrow&#xD;
&#xD;
          -  Patients with a history of major surgery except laparoscopic examination, endoscopic&#xD;
             intervention, or gastrojejunostomy&#xD;
&#xD;
          -  Patients who have contraindication of radiation therapy&#xD;
&#xD;
          -  Patients with HIV infection, chronic hepatitis B, chronic hepatitis C, or liver&#xD;
             cirrhosis&#xD;
&#xD;
          -  Female patients with childbearing age or pregnancy or breast feeding&#xD;
&#xD;
          -  Patients who are considered as inappropriate candidate by investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Hyeok Hwang, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-Hyeok Hwang, MD PhD</last_name>
    <phone>+82-31-787-7017</phone>
    <email>wooltong@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Hyeok Hwang, MD PhD</last_name>
      <phone>+82-31-787-7017</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>adenovirus</keyword>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoviridae Infections</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Suicide</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

